MarketBeat reports consensus rating for Harvard Bioscience, which is listed on Nasdaq. Benchmark has boosted its target price for the company's stock.
2 reports, 2 independent
Updated Aug 12
Gone quiet
Reached 2 outlets in its first 24 hours
- Reports
- 2
- Developments
- 1
- Repetition
- 50%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
MarketBeat reports consensus rating for Harvard Bioscience, which is listed on Nasdaq. Benchmark has boosted its target price for the company's stock.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Harvard Bioscience
company in Holliston, United States
Nothing else this week.
-
Nasdaq
American fully electronic stock exchange
-
Benchmark
venture capital firm
- The Bank of England, FED, and market experts are discussing how the ongoing Iran conflict and geopolitical tensions are driving up energy costs and influencing global financial rates.
- MarketBeat published a buy rating and target price increase for a company, with disclosures made under a Rule 10b5-1 trading plan.
-
MarketBeat
American personal finance blog
Related events
- BioHarvest Sciences Inc is listed on the Nasdaq stock exchange and is receiving analyst ratings and targets from MarketBeat.
- MarketBeat provided consensus ratings and target prices, while Jefferies Financial Group reaffirmed a hold rating on Target Healthcare REIT.
- MarketBeat has released its consensus rating and target price for Sunshine Biopharma, Inc.
- MarketBeat provides stock rating data for Vivos Therapeutics, which is listed on Nasdaq.
- Xenetic Biosciences and XTL Biopharmaceuticals are competing in the small-cap biopharmaceutical space, listed on the Nasdaq stock exchange.